An investigational therapeutic vaccine getting developed to treat herpes simplex virus-2.

Antigenics announces excellent results of AG-707 genital herpes vaccine Antigenics announced positive results with AG-707, an investigational therapeutic vaccine getting developed to treat herpes simplex virus-2 , the virus that triggers genital herpes, in infected individuals nolvadex review . Developed by Antigenics, the vaccine triggers a cellular immune response, stimulating both CD4+ and CD8+ T cells. Latest data suggest both of these arms of immunity are needed for successful treatment of genital herpes.D., research professor and investigator of Medication, Laboratory Medication and Global Health Medicine, University of Washington.

The researchers, centered at Manchester’s Wythenshawe Medical center, just centered on asthma which was triggered by tiny spores of common airborne fungi, which outnumber pollen grains by almost 1,000 to 1 and so are invisible to the naked eyes. Although most people don’t have a a reaction to them, when severe asthmatics inhale the spores their airways are believed to narrow, making it harder for them to breathe. Preliminary trials showed that the usage of anti-fungal drugs was found to lessen the incidence of hospitalisation by 75 per cent. It has led the scientists to go on a trial of the medication, itraconazole, with 100 asthmatics. Although the drug will not provide a treat for all asthmatics it might lessen attacks and for that reason save a large number of lives over time.